FDA Approves HRT Label Changes
The agency cited updated evidence in revising hormone therapy safety language.
By
Kathryn Wighton
February 12, 2026
Clinical Scorecard: FDA Approves HRT Label Changes
At a Glance
Category Detail
Condition Menopausal symptoms including hot flashes, vaginal dryness, and bone loss Key Mechanisms Hormone replacement therapy (HRT) alleviates vasomotor symptoms and prevents bone loss Target Population Women experiencing menopause, particularly those aged 45 to 64 years Care Setting Outpatient settings, including primary care and gynecology
Key Highlights
Removal of cardiovascular disease, breast cancer, and probable dementia risk statements from boxed warnings Approval of six menopausal hormone therapy products across four categories Initiation of labeling updates by the FDA in November 2025 Evidence supports benefits of HRT when initiated within 10 years of menopause onset Low utilization of hormone therapy among eligible women despite significant potential benefits Guideline-Based Recommendations
Diagnosis
Assess menopausal symptoms and quality of life impact Management
Consider HRT for moderate to severe vasomotor symptoms and prevention of osteoporosis Monitoring & Follow-up
Regular follow-up to assess symptom relief and any potential side effects Risks
Monitor for any emerging safety concerns despite removal of previous boxed warnings Patient & Prescribing Data
Approximately 41 million US women aged 45 to 64 years
Only about 2 million women aged 46 to 65 years received a prescription for hormone therapy in 2020
Clinical Best Practices
Educate patients on the benefits and risks of HRT Encourage timely initiation of therapy for optimal outcomes Utilize shared decision-making to tailor treatment plans Related Resources & Content
